X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian equity markets remain lackluster 
(Thu, 30 May 01:30 pm) 
 
Indian equity markets recovered some losses in last two hours of trade, though they hovered around the dotted line. Barring auto, FMCG and power sectors, all the sectoral indices are trading in the negative territory. Realty and Oil & gas stocks are witnessing maximum selling pressure.

BSE-Sensex is down by 12 points and NSE-Nifty is trading down by 8 points. While BSE Mid Cap is trading up by 0.05%, BSE Small Cap index is trading down by 0.25%. The rupee is trading at 56.19 to the US dollar.

Majority of the telecom stocks are trading in the red with Tata Tele and MTNL among the major losers. As per a leading financial daily, the Communications Minister has given a go-ahead for imposing a Rs 6.5 bn penalty on Bharti Airtel for providing subscriber local dialing (SLD) services in 13 regions during the period 2003-2005. SLD allows roaming customers to remain on the local network and skip roaming and STD charges. In June 2003, the Telecom Ministry had directed Bharti Airtel to stop providing SLD facility as it amounted to violation in the national routing plan. However as per Ministry officials, the company continued offering this service till 2005. This development is expected to further compound Bharti Airtel's woes as the company is already facing penalties for a host of alleged violations. The company's stock is currently down 1.6%.

Domestic pharma stocks are trading mixed with, Ipca Labs and Dishman Pharma trading firm while Cipla Ltd and Piramal Enterprises are trading weak. As per a financial daily, a US Congress member is seeking to review USFDA's (United States Food and Drugs Administration) probe into Ranbaxy. Steve Israel is a member of the US Congress. He has sent letter to the office of inspector general at the US department of health and human services asking for a complete review of the USFDA's actions during last 8 years. The letter calls to review the USFDA oversight policies and what steps can be taken by authorities to improve such events in the future. The letter also suggested for a complete review of the USFDA'S oversight of pharmaceutical drugs manufactured in foreign facilities. Earlier this month, Ranbaxy had pleaded guilty on various counts of federal and civil charges. The company had also agreed to pay a fine of US$ 500 m in order to settle the claims with the US Department of Justice. Ranbaxy was trading up by 0.12%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian equity markets remain lackluster". Click here!

  
 

S&P BSE TECK


Apr 28, 2017 (Close)

S&P BSE TECK 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS